Findings
CADe devices must meet classification requirements under 21 CFR 892.2050, including general and special controls, and require FDA clearance through 510(k) submissions.
Each new CADe device or significant modification must demonstrate substantial equivalence to a predicate device in terms of safety and effectiveness.
Robust testing and validation are necessary, including standalone and clinical performance assessments, to evaluate detection accuracy and false positive rates.
Devices with substantive technological differences or new intended uses may require clinical performance assessments.
Enrichment strategies for study populations (e.g., including challenging cases) are encouraged but should not bias performance evaluations.

Recommendations
Clearly describe the CADe algorithm, training datasets, scoring methodologies, and intended use in premarket submissions.
Conduct standalone performance assessments to measure detection accuracy and generalizability.
Compare new devices to predicate devices whenever possible, using consistent datasets and methodologies.
Develop and submit user training materials that address expected device performance, limitations, and appropriate usage scenarios.
Provide comprehensive labeling, including indications for use, directions, warnings, precautions, and performance metrics, to ensure clinician understanding and appropriate application.

Regulatory Considerations
All CADe devices under 21 CFR 892.2050 must comply with 510(k) premarket notification requirements, including general and special controls.
Changes to CADe algorithms or device characteristics must be evaluated for significant impact on safety and effectiveness, potentially requiring new submissions.
Devices with altered indications for use or significant technological differences may need additional clinical performance studies to demonstrate substantial equivalence.
Labeling must comply with 21 CFR Part 801 and provide sufficient information to describe the device, its intended use, and directions for use.
Manufacturers should consult FDA for guidance on substantial modifications or unique device characteristics.